Heparin Panpharma

Heparin Sodium, the active ingredient in Heparin Panpharma, is an anticoagulant presented as a sterile solution for intravenous and subcutaneous use. It is employed to prevent and treat clot formation in patients at risk of deep vein thrombosis, pulmonary embolism, and during cardiac or extracorporeal procedures.

GNH USA supplies Heparin Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable global distribution to healthcare facilities.

Heparin Sodium is used as an anticoagulant in several clinical situations that require inhibition of clot formation.

- Deep vein thrombosis (DVT): prevents clot extension and recurrence in patients with or at risk of DVT. - Pulmonary embolism (PE): treats existing emboli and reduces the risk of new clot development in the pulmonary arteries. - Cardiac surgery and extracorporeal circulation: provides anticoagulation to maintain circuit patency during procedures such as bypass. - Hemodialysis: prevents clot formation within dialysis circuits, ensuring effective treatment.

Heparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Bleeding: excessive or unexpected bleeding from any site. - Bruising: easy formation of bruises at injection sites or elsewhere. - Injection site pain or erythema: local discomfort or redness following subcutaneous administration. - Hypotension: transient low blood pressure, especially with rapid intravenous infusion.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop that can paradoxically increase clot risk. - Spinal or epidural hematoma: bleeding in the spinal canal, potentially causing neurologic deficits. - Severe allergic reactions: including anaphylaxis, urticaria, or angioedema. - Osteoporosis with long‑term use: decreased bone mineral density after prolonged therapy.

When using Heparin Sodium, clinicians should observe several safety measures to minimize complications.

- Monitor coagulation: regularly assess activated partial thromboplastin time (aPTT) or anti‑Xa levels to maintain therapeutic range. - Review patient history: avoid use in individuals with known heparin‑induced thrombocytopenia or active major bleeding. - Adjust for renal/hepatic impairment: consider dose modification in patients with significant organ dysfunction. - Concomitant anticoagulants: use caution when combined with other anticoagulant or antiplatelet agents, monitoring for additive bleeding risk. - Pregnancy and lactation: evaluate risk‑benefit carefully as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Heparin Sodium can interact with several medications, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid): - Warfarin: combined use markedly increases bleeding risk; avoid unless closely supervised. - Direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban: additive anticoagulation may cause severe hemorrhage. - Thrombolytic agents (e.g., alteplase): concurrent therapy can lead to uncontrolled bleeding. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): enhance gastrointestinal bleeding risk. - Antiplatelet drugs (e.g., aspirin, clopidogrel): increase overall bleeding tendency.

Moderate Interactions (Monitor Closely): - Aspirin or other low‑dose antiplatelet agents: monitor for signs of bleeding. - Glycoprotein IIb/IIIa inhibitors: observe platelet counts and bleeding parameters. - Corticosteroids: may potentiate gastrointestinal irritation and bleeding; assess risk.